Human Advanced Glycosylation End Product-Specific Receptor (AGER) Protein

Documentos del producto

Especificaciones del producto

Proteins and Peptides

Advanced Glycosylation End Product-Specific Receptor (AGER)

HEK293 cells

Activity: Not tested
Sequence Fragment: Met1-Ala342
Tag: C-terminal His tag

Human

Calculated MW: 37.51 kDa  Observed MW (SDS-PAGE): 45 kDa

Recombinant

>95% (SDS-PAGE)

20 µg

100 µg

500 µg

1 mg

Lyophilized

SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 5% - 8% Trehalose, Mannitol and 0.01% Tween-80.

Shipped within 5-15 working days.

Storage: Store lyophilized between -20 °C and -80°C.
Stability: Stable when stored reconstituted at 2-8°C for up to 1 week. Reconstituted aliquots are stable at -20°C for up to 3 months.
Shelf Life: 12 months.

No

Q15109

177

6214

RAGE,SCARJ1,sRAGE

Protein AGER

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Reconstitute in sterile H2O. Do not vortex.

Background

AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.